Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression

NCT04753970 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04753970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04753970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 9, 2021
Completion date
June 30, 2030
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, cerebral microbleeding, cerebral small vessel diseases, sporadic white matter disease